Business
Phase 2a results in ovarian cancer reported by Biomira's commercialization partner Prima BioMed
Phase 2a results in ovarian cancer reported by Biomira's commercialization partner Prima BioMed.
About this update from Skrr Exploration, Inc.
[{"type":"text","content":"\n\n\n\n\nEDMONTON, May 16 /CNW/ - Biomira Inc. (Nasdaq:BIOM) (TSX:BRA) today\nannounced its commercialization partner, Prima BioMed (ASX: PRR), reported\nfavorable results in its CVac(TM) ongoing phase 2a clinical trial in ovarian\ncancer. A second analysis of data made available to Prima BioMed's Scientific\nAdvisory Panel (SAP) indicated that so far 21 per cent of patients in the\ntrial had achieved either a clinical response to treatment or stabilization of\ntheir disease. Patients in the overall study are late stage progressive\novarian cancer patients with no therapeutic alternative. Fifteen per cent of\npatients having achieved either a clinical response to treatment or\nstabilization of their disease in the trial's patient population, for whom\nstandard therapies provide minimal benefit, is considered a benchmark response\nrate to demonstrate that a therapy has sufficient activity to warrant its\nprogression to a comparative clinical trial.\nThe primary objective of the trial is to determine whether CVac(TM), a\ncancer immunotherapy, can produce clinical responses or stabilization of\novarian cancer, as determined by monitoring the blood marker, CA125, a well\nrecognized tumour marker of disease activity. Twenty-eight ovarian cancer\npatients were recruited to the trial, all of whom had previously failed other\nforms of therapy and were assessed as having progressive disease by increases\nin CA125 levels. Twenty-one of these patients went on to complete the\nrequisite dosing (three injections) of CVac(TM) to qualify for inclusion in\nthe study.\nThe purpose of this analysis is to update the trial's SAP on safety and\nCA125 trends. Data included in this analysis were from patients who had\nreceived at least three injections of CVac(TM). This criterion excluded seven\npatients (of the 28 enrolled) who were withdrawn from the study before having\nreceived three injections. The results of 19 patients who had received the\nminimum of three doses were reviewed by the SAP and the data for a further two\npatients is yet to be analyzed. As a continuation of the second analysis, the\nSAP plans to review the patients' cellular immune response. This review is\nplanned for June 2006.\n\nBiomira/Prima BioMed Agreement\nThe agreement, originally negotiated with CancerVac, a wholly-owned\nsubsidiary of Prima BioMed, provides that Biomir...